.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Harvard Business School
US Army
Express Scripts
Fish and Richardson
Moodys
McKinsey
Dow
Accenture
AstraZeneca

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: RE42376

« Back to Dashboard

Which drugs does patent RE42376 protect, and when does it expire?


Patent RE42376 protects BOSULIF and is included in one NDA. There has been one Paragraph IV challenge on Bosulif.

Summary for Patent: RE42376

Title:Substituted 3-cyanoquinolines
Abstract: This invention provides compounds of formula I having the structure ##STR00001## wherein G.sub.1, G.sub.2, R.sub.1, R.sub.4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.
Inventor(s): Wissner; Allan (Ardsley, NY), Tsou; Hwei-Ru (New City, NY), Berger; Dan M. (New City, NY), Floyd, Jr.; Middleton B. (Suffern, NY), Hamann; Philip R. (Thiells, NY), Zhang; Nan (Bayside, NY), Frost; Philip (Morris Township, NJ)
Assignee: Wyeth Holdings Corporation (Madison, NJ)
Application Number:12/785,269
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes► Subscribe► SubscribeY
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-002Sep 4, 2012RXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: RE42376

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,297,258 Substituted 3-cyanoquinolines► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Farmers Insurance
Accenture
Boehringer Ingelheim
Queensland Health
Fish and Richardson
Healthtrust
Express Scripts
Federal Trade Commission
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot